{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:46:34Z","timestamp":1790837194825,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T00:00:00Z","timestamp":1526947200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["APP1102604"],"award-info":[{"award-number":["APP1102604"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"crossref","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13045-018-0617-1","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T13:00:50Z","timestamp":1526994050000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial"],"prefix":"10.1186","volume":"11","author":[{"given":"Jun","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Tatsugami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Young","family":"Rha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Lyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsoo","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Yeong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsi Chin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen Hwa","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene J.","family":"Carrasco-Alfonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupinder","family":"Nanua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qasim","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-2327","authenticated-orcid":false,"given":"Robert","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,22]]},"reference":[{"issue":"Suppl 7","key":"617_CR1","doi-asserted-by":"publisher","first-page":"vii65","DOI":"10.1093\/annonc\/mds227","volume":"23","author":"B Escudier","year":"2012","unstructured":"Escudier B, Eisen T, Porta C, Patard JJ, Khoo V, Algaba F, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii65\u201371.","journal-title":"Ann Oncol"},{"issue":"3","key":"617_CR2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","volume":"22","author":"RJ Motzer","year":"2004","unstructured":"Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22(3):454\u201363. https:\/\/doi.org\/10.1200\/JCO.2004.06.132 .","journal-title":"J Clin Oncol"},{"issue":"10","key":"617_CR3","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1038\/sj.bjc.6605366","volume":"101","author":"R Kumar","year":"2009","unstructured":"Kumar R, Crouthamel MC, Rominger DH, Gontarek RR, Tummino PJ, Levin RA, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer. 2009;101(10):1717\u201323. https:\/\/doi.org\/10.1038\/sj.bjc.6605366 .","journal-title":"Br J Cancer"},{"key":"617_CR4","unstructured":"European Medicines Agency. Votrient (pazopanib) authorisation details. 2010. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/001141\/human_med_001337.jsp&murl=menus\/medicines\/medicines.jsp&mid=WC0b01ac058001d124&jsenabled=true Accessed 12 May 2018."},{"key":"617_CR5","unstructured":"United States Food and Drug Administration. Pazopanib [approval notice]. 2009. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2009\/022465s000ltr.pdf ."},{"key":"617_CR6","unstructured":"European Medicines Agency. Sutent (sunitinib) authorisation details. 2006. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000687\/human_med_001069.jsp&mid=WC0b01ac058001d124 ."},{"key":"617_CR7","unstructured":"United States Food and Drug Administration. Sunitinb [approval notice]. 2006. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/021938_S000_Sutent_Approv.pdf ."},{"issue":"8","key":"617_CR8","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1303989 .","journal-title":"N Engl J Med"},{"issue":"7","key":"617_CR9","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/cncr.29888","volume":"122","author":"JL Beaumont","year":"2016","unstructured":"Beaumont JL, Salsman JM, Diaz J, Deen KC, McCann L, Powles T, et al. Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. Cancer. 2016;122(7):1108\u201315. https:\/\/doi.org\/10.1002\/cncr.29888 .","journal-title":"Cancer"},{"issue":"1","key":"617_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2133\/dmpk.DMPK-11-RV-111","volume":"27","author":"K Kurose","year":"2012","unstructured":"Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics\/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet. 2012;27(1):9\u201354.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"617_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1517\/17425255.2012.657626","volume":"8","author":"J McGraw","year":"2012","unstructured":"McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol. 2012;8(3):371\u201382. https:\/\/doi.org\/10.1517\/17425255.2012.657626 .","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"617_CR12","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1093\/annonc\/mdq150","volume":"21","author":"T Mizuno","year":"2010","unstructured":"Mizuno T, Terada T, Kamba T, Fukudo M, Katsura T, Nakamura E, et al. ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. Ann Oncol. 2010;21(6):1382\u20133. https:\/\/doi.org\/10.1093\/annonc\/mdq150 .","journal-title":"Ann Oncol"},{"issue":"3","key":"617_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):205\u201316.","journal-title":"J Natl Cancer Inst"},{"key":"617_CR14","unstructured":"National Cancer Institute Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf ."},{"issue":"1","key":"617_CR15","first-page":"31","volume":"23","author":"M Kitada","year":"2003","unstructured":"Kitada M. Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6. Int J Clin Pharmacol Res. 2003;23(1):31\u20135.","journal-title":"Int J Clin Pharmacol Res"},{"issue":"2","key":"617_CR16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1634\/theoncologist.11-2-126","volume":"11","author":"S Bernard","year":"2006","unstructured":"Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist. 2006;11(2):126\u201335. https:\/\/doi.org\/10.1634\/theoncologist.11-2-126 .","journal-title":"Oncologist"},{"issue":"3","key":"617_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1517\/17425250902800153","volume":"5","author":"VH Phan","year":"2009","unstructured":"Phan VH, Moore MM, McLachlan AJ, Piquette-Miller M, Xu H, Clarke SJ. Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opin Drug Metab Toxicol. 2009;5(3):243\u201357. https:\/\/doi.org\/10.1517\/17425250902800153 .","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"617_CR18","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jhep.2010.09.028","volume":"54","author":"CF Xu","year":"2011","unstructured":"Xu CF, Reck BH, Goodman VL, Xue Z, Huang L, Barnes MR, et al. Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol. 2011;54(6):1237\u201343. https:\/\/doi.org\/10.1016\/j.jhep.2010.09.028 .","journal-title":"J Hepatol"},{"issue":"9","key":"617_CR19","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/sj.bjc.6605653","volume":"102","author":"CF Xu","year":"2010","unstructured":"Xu CF, Reck BH, Xue Z, Huang L, Baker KL, Chen M, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert\u2019s syndrome UGT1A1 polymorphism. Br J Cancer. 2010;102(9):1371\u20137. https:\/\/doi.org\/10.1038\/sj.bjc.6605653 .","journal-title":"Br J Cancer"},{"issue":"7","key":"617_CR20","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1002\/cncr.26491","volume":"118","author":"JJ Kim","year":"2012","unstructured":"Kim JJ, Vaziri SA, Rini BI, Elson P, Garcia JA, Wirka R, et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer. 2012;118(7):1946\u201354. https:\/\/doi.org\/10.1002\/cncr.26491 .","journal-title":"Cancer"},{"issue":"26","key":"617_CR21","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1200\/JCO.2008.21.7679","volume":"27","author":"NP van Erp","year":"2009","unstructured":"van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol. 2009;27(26):4406\u201312. https:\/\/doi.org\/10.1200\/JCO.2008.21.7679 .","journal-title":"J Clin Oncol"},{"issue":"1","key":"617_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/clpt.2014.47","volume":"96","author":"MH Diekstra","year":"2014","unstructured":"Diekstra MH, Klumpen HJ, Lolkema MP, Yu H, Kloth JS, Gelderblom H, et al. Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662. Clin Pharmacol Ther. 2014;96(1):81\u20139. https:\/\/doi.org\/10.1038\/clpt.2014.47 .","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"617_CR23","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1101\/gr.9.8.677","volume":"9","author":"ST Sherry","year":"1999","unstructured":"Sherry ST, Ward M, Sirotkin K. dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res. 1999;9(8):677\u20139.","journal-title":"Genome Res"},{"issue":"1","key":"617_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13256-016-1185-z","volume":"11","author":"S Takasaki","year":"2017","unstructured":"Takasaki S, Kikuchi M, Kawasaki Y, Ito A, Arai Y, Yamaguchi H, et al. Severe toxicity induced by accumulation of active sunitinib metabolite in a Japanese patient with renal cell carcinoma: a case report. J Med Case Rep. 2017;11(1):28. https:\/\/doi.org\/10.1186\/s13256-016-1185-z .","journal-title":"J Med Case Rep"},{"issue":"suppl 10","key":"617_CR25","doi-asserted-by":"publisher","first-page":"S1558","DOI":"10.21037\/tcr.2017.09.09","volume":"6","author":"JA Touma","year":"2017","unstructured":"Touma JA, McLachlan AJ, Gross AS. The role of ethnicity in personalized dosing of small molecule tyrosine kinase inhibitors used in oncology. Transl Cancer Res. 2017;6(suppl 10):S1558\u201391.","journal-title":"Transl Cancer Res"},{"issue":"15","key":"617_CR26","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.1158\/1078-0432.CCR-09-0344","volume":"15","author":"PH O\u2019Donnell","year":"2009","unstructured":"O\u2019Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res. 2009;15(15):4806\u201314. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0344 .","journal-title":"Clin Cancer Res"},{"issue":"1","key":"617_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3349\/ymj.2013.54.1.1","volume":"54","author":"N Saijo","year":"2013","unstructured":"Saijo N. The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology. Yonsei Med J. 2013;54(1):1\u201314. https:\/\/doi.org\/10.3349\/ymj.2013.54.1.1 .","journal-title":"Yonsei Med J"},{"issue":"4","key":"617_CR28","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00280-014-2374-3","volume":"73","author":"M Inada-Inoue","year":"2014","unstructured":"Inada-Inoue M, Ando Y, Kawada K, Mitsuma A, Sawaki M, Yokoyama T, et al. Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors. Cancer Chemother Pharmacol. 2014;73(4):673\u201383. https:\/\/doi.org\/10.1007\/s00280-014-2374-3 .","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"617_CR29","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/s10637-009-9306-9","volume":"28","author":"K Shirao","year":"2010","unstructured":"Shirao K, Nishida T, Doi T, Komatsu Y, Muro K, Li Y, et al. Phase I\/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Investig New Drugs. 2010;28(6):866\u201375. https:\/\/doi.org\/10.1007\/s10637-009-9306-9 .","journal-title":"Investig New Drugs"},{"issue":"11","key":"617_CR30","doi-asserted-by":"publisher","first-page":"977","DOI":"10.2165\/11593370-000000000-00000","volume":"29","author":"AF Mohamed","year":"2011","unstructured":"Mohamed AF, Hauber AB, Neary MP. Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma. PharmacoEconomics. 2011;29(11):977\u201388. https:\/\/doi.org\/10.2165\/11593370-000000000-00000 .","journal-title":"PharmacoEconomics"},{"issue":"6","key":"617_CR31","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3111\/13696998.2012.708689","volume":"15","author":"MK Wong","year":"2012","unstructured":"Wong MK, Mohamed AF, Hauber AB, Yang JC, Liu Z, Rogerio J, et al. Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma. J Med Econ. 2012;15(6):1139\u201348. https:\/\/doi.org\/10.3111\/13696998.2012.708689 .","journal-title":"J Med Econ"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0617-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-018-0617-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0617-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:28:26Z","timestamp":1661300906000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-018-0617-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,22]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["617"],"URL":"https:\/\/doi.org\/10.1186\/s13045-018-0617-1","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,22]]},"assertion":[{"value":"14 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institutional review board or ethics committee at each participating center and was conducted in accordance with the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines. A data and safety monitoring board reviewed safety data during the study. Written informed consent was obtained from each patient prior to participation in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Shunji Takahashi received research funding and honoraria from Novartis Pharmaceuticals Corporation. Arun Azad received consultant, speakers bureau, and honoraria from Novartis Pharmaceuticals Corporation. Hirotsugu Uemura received research funding, speakers bureau, and honoraria from Novartis Pharmaceuticals Corporation and received research funding, speakers bureau, and honoraria from Pfizer. Bhupinder Nanua, Jackie Han, and Qasim Ahmad are employees of Novartis Pharmaceuticals Corporation. Marlene J. Carrasco-Alfonso is an employee and shareholder of Novartis Pharmaceuticals Corporation. Jun Guo, Jie Jin, Mototsugu Oya, Katsunori Tatsugami, Sun Young Rha, Jae-Lyun Lee, Jinsoo Chung, Ho Yeong Lim, Hsi Chin Wu, Yen Hwa Chang, Ian D. Davis, Robert Motzer report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"69"}}